Endocyte appoints Novartis vet David Meek as chief commercial officer

Monday, July 30, 2012 03:49 PM

Endocyte, an Indianapolis, Ind.-based biopharmaceutical company focused on cancer and inflammatory diseases, has appointed David Meek to the newly created position of chief commercial officer. He will be responsible for the development of Endocyte’s commercial team and overall commercial strategy and execution.

Meek brings more than 20 years of pharmaceutical industry experience, including general management in North America and Europe, and numerous successful launches for oncology and specialty products. He comes to Endocyte after more than seven years at Novartis Pharma, where he was most recently the head of Northern and Central Europe oncology and launched key new oncology products and indications for Novartis. Previously, Meek served as president and CEO of Novartis Pharmaceuticals Canada, where he oversaw the launch of Lucentis and other specialty products. Prior to his roles at Novartis, Meek served at Johnson & Johnson for 15 years, where he held a variety of senior sales and marketing roles across multiple therapeutic areas, including oncology.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

July 28

WCG acquires Alliance Biosciences to expand its biosafety oversight capabilities, ensure compliance

Facilitated review meetings for protocol design catching on, decreasing amendments, complexity

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

July

IRB market consolidating rapidly
Private equity driving a new commercial ethical review landscape

Lessons learned from medical device trials
Smaller, faster, more flexible trials hold important insights for pharmaceutical innovation

Already a subscriber?
Log in to your digital subscription.

Purchase the July issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

June

CRO market poised for growth and consolidation
Sponsors expanding pipelines, shrinking infrastructure fuel strategic outsourcing

Strategies for success evolving in phase I space
Sites see increasing complexity, more patients, greater focus on efficacy

Already a subscriber?
Log in to your digital subscription.

Purchase the June issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs